Reviewing Kindred Biosciences Inc. (KIN)’s and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX)’s results

Kindred Biosciences Inc. (NASDAQ:KIN) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) compete against each other in the Biotechnology sector. We will contrast them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kindred Biosciences Inc. N/A 633.10 43.98M -1.49 0.00
Protalix BioTherapeutics Inc. 9.69M 6.87 51.38M -0.35 0.00

Table 1 demonstrates Kindred Biosciences Inc. and Protalix BioTherapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.


Table 2 provides us the net margins, return on assets and return on equity of both businesses.

Net Margins Return on Equity Return on Assets
Kindred Biosciences Inc. 0.00% -46.2% -43.3%
Protalix BioTherapeutics Inc. -530.24% 0% 0%

Analyst Recommendations

The table given features the ratings and recommendations for Kindred Biosciences Inc. and Protalix BioTherapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Kindred Biosciences Inc. 0 0 1 3.00
Protalix BioTherapeutics Inc. 0 0 0 0.00

$25 is Kindred Biosciences Inc.’s consensus price target while its potential upside is 138.55%.

Institutional and Insider Ownership

Roughly 66.8% of Kindred Biosciences Inc. shares are held by institutional investors while 9.82% of Protalix BioTherapeutics Inc. are owned by institutional investors. Insiders held 6.3% of Kindred Biosciences Inc. shares. Competitively, Protalix BioTherapeutics Inc. has 6.23% of it’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Kindred Biosciences Inc. -9.41% -15.56% -12% 20.78% 63.18% 30.37%
Protalix BioTherapeutics Inc. -3.09% -9.42% -14.23% -9.66% -35.18% -36.46%

For the past year Kindred Biosciences Inc. has 30.37% stronger performance while Protalix BioTherapeutics Inc. has -36.46% weaker performance.


On 6 of the 10 factors Kindred Biosciences Inc. beats Protalix BioTherapeutics Inc.

Kindred Biosciences, Inc., a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. The company's other small molecule product candidates consist of KIND-014 for treatment of equine gastric ulcers in horses; and KIND-015 for the management of clinical signs related to equine metabolic syndrome. It is also developing biologics programs, including KIND-510, a feline recombinant erythropoietin for the control of non-regenerative anemia in cats; KIND-011, an anti-tumor necrosis factor (TNF) to treat newborn foals; and canine atopic dermatitis, an immune-mediated inflammatory, chronic skin disease related to allergies. In addition, the company engages in the development of other biologic product candidates, such as KIND-502 to treat allergic and immune-mediated diseases; KIND-0888, an antibody that targets CD20; various antibodies that target cytokines involved in atopic dermatitis; KIND-509, an antibody that targets the canine TNF; and KIND-Bodies, a biologics scaffold technology. Further, it is developing anti-IL31, anti-IL17, and anti-IL4/13 sink antibodies for treating atopic dermatitis in dogs; anti-TNF antibody for inflammatory bowel disease in dogs; anti-IgE antibody for treating allergic diseases in dogs; anti-VEGF antibody for cancer in dogs; anti-CD20 for treating cancer and autoimmune diseases in dogs; and checkpoint inhibitors to treat cancer in dogs. Kindred Biosciences, Inc. was founded in 2012 and is headquartered in Burlingame, California.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase II clinical trials to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.